Tarceva is an oral, once-daily, reversible inhibitor of the EGFR signalling pathway. It is indicated as monotherapy for the treatment of patients with advanced non-small cell lung cancer whose tumours are driven by common EGFR gene-activating mutations. It is also indicated for patients with advanced pancreatic cancer in combination with chemotherapy.
Tarceva is available in more than 100 countries worldwide.
This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.